Filana Therapeutics, Inc.
FLNA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.79M
Close$
$1.98
200.5% upside
Current Fair Value
200.5% upsideUndervalued by 200.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $31.79 Million |
|---|---|
| Enterprise Value | $-50,894,336.00 |
| Earnings per Share | $-1.88 |
| Beta | -0.66 |
| Outstanding Shares | 48,308,000 |
Return
| Return on Equity | -66.47% |
|---|---|
| Return on Assets | -40.69% |
| Return on Invested Capital | 55.97% |
Valuation & Multiples
| P/E Ratio | -0.73 |
|---|---|
| PEG | 0.91 |
| Price to Sales | - |
| Price to Book Ratio | 0.66 |
| Enterprise Value to Revenue | -22.52 |
| Enterprise Value to EBIT | -0.53 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS Estimate
$-0.24
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$-0.24
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cassava Sciences Inc
29 employees
CEO: Remi Barbier
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.